CD19 and precursor B-cell acute lymphoblastic leukemia: As an example, antigen-negative relapses with a CD19-/CD22dim phenotype concerned only 6% of relapsing patients (42), against 7-25% (7-9% for adult, and 18-25% for pediatric B-ALL) for CD19 monospecific CAR-T treatments (6, 44).